[Gene therapy for malignant glioma]

Area of Science:

• Integrates life sciences and computer technologies for novel medical fields.
• Focuses on genetic medicines, including genetic diagnosis and gene therapy.
• Explores advancements in pharmacogenomics and nutrigenomics.

Context:

• Gene therapy for malignant brain tumors includes suicide gene therapy (herpes simplex virus-thymidine kinase/ganciclovir) and immuno-gene therapy (cytokine genes).
• A new gene therapy protocol utilizes cationic multilamellar liposomes carrying the interferon-beta (IFN-beta) gene as a vector.
• Clinical trials for IFN-beta gene therapy in malignant glioma patients commenced in April 2000.

Purpose:

• To introduce the current status and future prospects of gene therapy for malignant brain tumors.
• To present a novel gene therapy approach using IFN-beta gene delivered via cationic liposomes.
• To evaluate the safety and usefulness of this gene therapy in clinical trials.

Summary:

• A novel gene therapy protocol employing cationic multilamellar liposomes with the interferon-beta (IFN-beta) gene has been developed.
• Clinical trials involving five malignant glioma patients treated with this IFN-beta gene therapy have been initiated.
• Ongoing evaluation focuses on the safety and efficacy of this gene therapy for brain tumors.

Impact:

• Presents a new vector system (cationic liposomes) for gene delivery in cancer therapy.
• Contributes to the advancement of genetic medicines for challenging diseases like malignant glioma.
• Highlights the potential of interferon-beta gene therapy in the context of brain tumor treatment.